Post-bariatric hypoglycaemia
Tidsskr Nor Laegeforen. 2025 May 6;145(6).
doi: 10.4045/tidsskr.24.0396.
Print 2025 May 13.
[Article in
English,
Norwegian]
Affiliations
- 1 Senter for sykelig overvekt, Avdeling for endokrinologi, sykelig overvekt og forebyggende medisin, Oslo universitetssykehus, Aker.
- 2 Medisinsk avdeling, Sykehuset i Vestfold, Tønsberg.
- 3 Avdeling for endokrinologi, sykelig overvekt og forebyggende medisin, Oslo universitetssykehus, Aker, og, Institutt for klinisk medisin, Universitetet i Oslo.
- 4 Avdeling for for gastro- og barnekirurgi, Oslo universitetssykehus, Ullevål, og, Institutt for klinisk medisin, Universitetet i Oslo.
Abstract
Awareness of post-bariatric hypoglycaemia has increased in recent years. The condition appears to be more prevalent than previously estimated, when mild to moderate cases are taken into account. Most patients respond well to dietary adjustments, while a small proportion may require assistance or experience seizures or syncope. Hypoglycaemia is associated with both weight-dependent and weight-independent mechanisms. Key factors include improved insulin sensitivity and increased secretion of incretin hormones such as glucagon-like peptide 1 (GLP-1). The primary goal of treatment is to minimise the postprandial fluctuations in blood glucose and insulin levels. Although certain medications may help to alleviate symptoms, they are rarely used. This clinical overview aims to raise awareness of hypoglycaemia following bariatric surgery and to highlight key considerations for healthcare professionals who encounter these patients.
MeSH terms
-
Bariatric Surgery* / adverse effects
-
Blood Glucose / analysis
-
Blood Glucose / metabolism
-
Glucagon-Like Peptide 1 / metabolism
-
Humans
-
Hypoglycemia* / diagnosis
-
Hypoglycemia* / drug therapy
-
Hypoglycemia* / etiology
-
Hypoglycemia* / therapy
-
Insulin / blood
-
Insulin Resistance
-
Postoperative Complications / etiology
Substances
-
Insulin
-
Blood Glucose
-
Glucagon-Like Peptide 1